RT Journal Article SR Electronic T1 Whole-Cell Dissociated Suspension Analysis in Human Brain Neurodegenerative Disease: A Pilot Study JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.01.08.21249455 DO 10.1101/2021.01.08.21249455 A1 Geidy E. Serrano A1 Jessica E. Walker A1 Anthony J. Intorcia A1 Michael J. Glass A1 Richard A. Arce A1 Ignazio S. Piras A1 Joshua S. Talboom A1 Courtney M. Nelson A1 Brett D. Cutler A1 Lucia I. Sue A1 Lih-Fen Lue A1 Matthew Huentelman A1 Thomas G. Beach YR 2021 UL http://medrxiv.org/content/early/2021/01/09/2021.01.08.21249455.abstract AB Biochemical analysis of human brain tissue is typically done by homogenizing whole pieces of brain and separately characterizing the proteins, RNA, DNA, and other macromolecules within. While this has been sufficient to identify substantial changes, there is little ability to identify small changes or alterations that may occur in subsets of cells. To effectively investigate the biochemistry of disease in the brain, with its different cell types, we must first separate the cells and study them as phenotypically defined populations or even as individuals. In this project, we developed a new method for the generation of whole-cell-dissociated-suspensions (WCDS) in fresh human brain tissue that could be shared as a resource with scientists to study single human cells or populations. Characterization of WCDS was done in paraffin-embedded sections stained with H&E, and by phenotyping with antibodies using immunohistochemistry and fluorescence-activated cell sorting (FACS). Additionally, we compared extracted RNA from WCDS with RNA from adjacent intact cortical tissue, using RT-qPCR for cell-type-specific RNA for the same markers as well as whole transcriptome sequencing. More than 11,626 gene transcripts were successfully sequenced and classified using an external database either as being mainly expressed in neurons, astrocytes, microglia, oligodendrocytes, endothelial cells, or mixed (in two or more cell types). This demonstrates that we are currently capable of producing WCDS with a full representation of different brain cell types combined with RNA quality suitable for use in biochemical analysis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Brain and Body Donation Program is supported by the National Institute on Aging (P30 AG19610 Arizona Alzheimer's Disease Core Center), the Arizona Department of Health Services (contract 211002, Arizona Alzheimer's Research Center), the Arizona Biomedical Research Commission (contracts 4001, 0011, 05-901 and 1001 to the Arizona Parkinson's Disease Consortium) and the Michael J. Fox Foundation for Parkinson's Research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was done with volunteers in the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND) and the Brain and Body Donation Program (BBDP; www.brainandbodydonationprogram.org), a longitudinal clinicopathological study of healthy aging, cognition, and movement in the elderly since 1996 in Sun City, Arizona (Beach et al., 2015; Beach et al., 2008). All subjects signed an Institutional Review Board-approved informed consent reviewed by reviewed by the Western IRB in Puyallup, Washington, allowing both clinical assessments during life and several options for brain and bodily organ donation after death.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available by request and registration to www.brainandbodydonationprogram.org https://www.brainandbodydonationprogram.org